SHANGHAI, Dec 3 (Reuters) - China stocks edged lower on
Thursday after the U.S. House of Representatives passed a bill
that threatened to delist Chinese companies off U.S. stock
exchanges, a move likely to further ratchet up tensions between
Washington and Beijing.
** Measures taking a harder line on Chinese business and trade
practices generally pass U.S. Congress with large margins. Both
Democrats and Donald Trump's fellow Republicans echo the
president's hard line against Beijing, which became fiercer this
year as Trump blamed China for the coronavirus ravaging the
** At the midday break, the Shanghai Composite index was
down 0.09% at 3,446.19 points, while China's blue-chip CSI300
index slipped 0.11%.
** Chinese H-shares listed in Hong Kong fell 0.07% to
10,566.52, while the Hang Seng Index was up 0.56% at
** The smaller Shenzhen index was up 0.17%, the start-up
board ChiNext Composite index was higher by 1.25% and
Shanghai's tech-focused STAR50 index was up 0.56%.
** Pharmaceuticals outperformed the market, with vaccine-related
stocks limiting losses in the index, after the Institute of
Microbiology at the Chinese Academy of Sciences said it worked
with China's Chongqing Zhifei to carry out a phase
III trial of a coronavirus vaccine in China's Hunan province in
November. The company was up 7% by midday, while the healthcare
sub-index rose 3.11%.
** Around the region, MSCI's Asia ex-Japan stock index
was firmer by 0.27% while Japan's Nikkei index
was up 0.01%.
** The largest percentage losses in the Shanghai index were
Dalian Sunasia Tourism Holding Co Ltd, down 10.009%,
followed by Changzhou Langbo Sealing Technologies Co Ltd
, losing 9.99% and Xilinmen Furniture Co Ltd
, down by 8.858%.
** So far this year, the Shanghai stock index is up 13% and the
CSI300 climbed 23.6%, while China's H-share index listed in Hong
Kong dropped 5.4%. Shanghai stocks advanced 1.6% so far this
(Reporting by Winni Zhou and Andrew Galbraith, Editing by